Study investigated nivolumab combined with brentuximab vedotin for treatment of relapsed t-cell lymphomas.
Home / Resource Library / Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma